Abbott Laboratories
Search results
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection.
Apr 18, 2022 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
May 7, 2024 · AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
Jul 12, 2024 · AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis. Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12... July 10, 2024.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
